10.36 USD
▼-0.80-7.17%
盘后 10.56 +1.93%
2026-09-15
市值
$139.78M
市盈率
—
EPS
-6.82
股息率
—
52 周区间
4.86 – 17.40
成交量
495.83K
Beta
2.15
目标价
28.87
52W 低 4.8652W 高 17.40
价格走势
公司简介
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain met...